Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
03/28/2013
Trade Name:
Karbinal ER
Generic Name or Proper Name (*):
carbinoxamine maleate
Indications Studied:
Relief of seasonal and perennial allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis due to inhalant allergens and foods, mild uncomplicated allergic skin manifestations of urticaria and angioedema, dermatographism, as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled, and amelioration of the severity of allergic reactions to blood or plasma
Label Changes Summary:
Approved for use in 2-17 years Efficacy and safety is based on demonstration of bioequivalence to the immediate release product Deaths have been reported in children younger than 2 years who were taking carbinoxamine containing drug products. Therefore, Karbinal ER is contraindicated in children younger than 2 years of age and in nursing mothers. Carbinoxamine may diminish mental alertness or produce sedation in children Paradoxical reactions with excitation are more likely in younger children Karbinal ER must be measured with an accurate milliliter measuring device Information on safety, dosing, and adverse reactions •New dosage form
Product Labeling:
Labeling
PREA(P):
P
Sponsor:
Tris Pharma, Inc.
NNPS:
TRUE'
Therapeutic Category:
Antihistamine
-
-